Absence of Monocyte Chemoattractant Protein 1 in Mice Leads to Decreased Local Macrophage Recruitment and Antigen-Specific T Helper Cell Type 1 Immune Response in Experimental Autoimmune Encephalomyelitis by Huang, DeRen et al.
 
J. Exp. Med. 
 
Ó
 
 The Rockefeller University Press • 0022-1007/2001/03/713/13 $5.00
Volume 193, Number 6, March 19, 2001 713–725
http://www.jem.org/cgi/content/full/193/6/713
 
713
 
Absence of Monocyte Chemoattractant Protein 1 in Mice 
Leads to Decreased Local Macrophage Recruitment and 
Antigen-speciﬁc T Helper Cell Type 1 Immune Response in 
Experimental Autoimmune Encephalomyelitis
 
By DeRen Huang,
 
*
 
 Jintang Wang,
 
*
 
 Pia Kivisakk,
 
* 
 
Barrett J. Rollins,
 
‡ 
 
and Richard M. Ransohoff
 
*
 
From the 
 
*
 
Department of Neurosciences, Lerner Research Institute, The Cleveland Clinic Foundation, 
Cleveland, Ohio 44195; and the 
 
‡
 
Department of Adult Oncology, Dana-Farber Cancer Institute, 
Harvard Medical School, Boston, Massachusetts 02115
 
Abstract
 
Monocyte chemoattractant protein (MCP)-1 plays a critical role in innate immunity by direct-
ing the migration of monocytes into inflammatory sites. Recent data indicated a function for
this chemokine in adaptive immunity as a regulator of T cell commitment to T helper cell type
2 (Th2) effector function. Studies in a Th1-dependent animal model, experimental autoim-
mune encephalomyelitis (EAE), showed that MCP-1 was highly expressed in the central ner-
vous system (CNS) of affected rodents, and MCP-1 antibodies could block relapses of the dis-
ease. Mice deficient for the major MCP-1 receptor, CC chemokine receptor (CCR)2, did not
develop EAE after active immunization but generated effector cells that could transfer the dis-
ease to naive wild-type recipients. We analyzed EAE in mice deficient for MCP-1 to define
the relevant ligand for CCR2, which responds to murine MCP-1, MCP-2, MCP-3, and
MCP-5. We found that C57BL/6 MCP-1–null mice were markedly resistant to EAE after ac-
tive immunization, with drastically impaired recruitment of macrophages to the CNS, yet able
to generate effector T cells that transferred severe disease to naive wild-type recipients. By con-
trast, adoptive transfer of primed T cells from wild-type mice into naive MCP-1–null recipi-
ents did not mediate clinical EAE. On the SJL background, disruption of the MCP-1 gene
produced a milder EAE phenotype with diminished relapses that mimicked previous findings
using anti–MCP-1 antibodies. There was no compensatory upregulation of MCP-2, MCP-3,
or MCP-5 in MCP-1–null mice with EAE. These results indicated that MCP-1 is the major
CCR2 ligand in mice with EAE, and provided an opportunity to define the role of MCP-1 in
 
EAE. Compared with wild-type littermates, MCP-1
 
2
 
/
 
2
 
 mice exhibited reduced expression of
interferon 
 
g
 
 in draining lymph node and CNS and increased antigen-specific immunoglobulin
G1 antibody production. Taken together, these data demonstrate that MCP-1 is crucial for
Th1 immune responses in EAE induction and that macrophage recruitment to the inflamed
CNS target organ is required for primed T cells to execute a Th1 effector program in EAE.
Key words: autoimmune disease • chemokine • chemokine receptor • macrophage • T helper 
cell type 1/T helper cell type 2
 
Introduction
 
Chemokines are small proteins (8–12 kD) divided into four
subfamilies (CXC, CC, C, and CX3C) according to the
organization of positionally conserved cysteine residues (1).
Monocyte chemoattractant protein 1 (MCP-1)
 
1 
 
is a proto-
type CC chemokine, active towards monocytes, dendritic
cells, and NK cells, thereby playing an important role in in-
 
Address correspondence to Dr. R.M. Ransohoff, Department of Neuro-
sciences NC30, Lerner Research Institute, The Cleveland Clinic Founda-
tion, 9500 Euclid Ave., Cleveland, OH 44195. Phone: 216-444-8939;
Fax: 216-444-7927; E-mail: ransohr@ccf.org
 
1
 
Abbreviations used in this paper: 
 
CCR, CC chemokine receptor; CNS,
central nervous system; EAE, experimental autoimmune encephalomyelitis;
 
IP-10, IFN-
 
g
 
–inducible 10-kD protein; MCP, monocyte chemoattractant
protein; MIP, macrophage inflammatory protein; MNC, mononuclear cell;
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lipid protein; RANTES, regulated upon activation, normal T cell expressed
and secreted; RPA, RNase protection assay; RT, reverse transcription;
TCA, T cell activation gene. 
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EAE in MCP-1–deficient Mice
 
nate immunity (2–7). However, MCP-1 is also a crucial
factor for the development of adaptive Th2 responses. In
this regard, MCP-1 directs the differentiation of Th0 cells
to Th2 in vitro
 
 
 
(8) by a mechanism dependent on IL-4
 
.
 
Administration of anti–MCP-1 Abs (9) or disruption of the
MCP-1 gene (2) significantly reduced the size of schisto-
some egg antigen (SEA) secondary granulomata, a Th2-
dominant disease model. Conversely, local overexpression
of MCP-1 increased the size of SEA secondary granulo-
mata (10). Immunization with trinitrophenol-derivatized
ovalbumin plus IFA elicited a reduced Th2 and unaltered
Th1 response in MCP-1–deficient (MCP-1
 
2
 
/
 
2
 
) mice.
MCP-1
 
2
 
/
 
2
 
 mice of Balb/c strain were relatively resistant to
 
Leishmania major
 
 infection, indicating that lack of MCP-1
led to reduced Th2 immunity (11).
Experimental autoimmune encephalomyelitis (EAE), a
model for autoimmune demyelination of the central ner-
vous system (CNS), has been widely employed to explore
pathogenic mechanisms underlying the human disease
multiple sclerosis (MS [12, 13]). The generation of myelin
protein–reactive T cells is an immunological hallmark of
both EAE and MS and is required for disease expression in
EAE. These autoreactive T cells traffic to the CNS, and
initiate inflammation and destruction of CNS myelin with
consequent neurological impairment (14, 15).
Th1-type T cells, producing IFN-
 
g
 
, IL-2, and TNF-
 
b
 
,
are associated with cellular immune responses, delayed-
type hypersensitivity, and macrophage activation, whereas
Th2-type T cells, producing IL-4, IL-5, and IL-10, are im-
portant for humoral immune responses (16, 17). The dy-
namic interplay and reciprocal inhibition between Th1 and
Th2 cytokines has been demonstrated in numerous re-
search reports. IL-4 is a major factor that governs Th2 dif-
ferentiation and inhibits the development of IFN-
 
g
 
–secret-
ing cells (18). The activation of macrophages and the
production of Th1 cytokines such as IFN-
 
g
 
 can also be in-
hibited by IL-10 (19). Most encephalitogenic T cell clones
examined are Th1 polarized (20–22), although exceptions
have been reported (23). Th1 cytokines are markedly ele-
vated in the CNS of animals during EAE attacks whereas
Th2 cytokines are associated with disease recovery (24). IL-
4–induced immune deviation is beneficial for recovery
from EAE (25); EAE can be prevented and/or reversed by
myelin antigen–specific T cells that are genetically trans-
duced with either IL-4 or IL-10 genes (26, 27); anti–IL-4
treatment reverses the tolerance induced by an altered pep-
tide ligand (28), and absence of IL-4 in gene-targeted mice
increases the severity of EAE (29). In summary, Th1 im-
mune responses are pathogenic and Th2 responses are pro-
tective in the initiation and evolution of EAE.
However, antigen-specific T cells constitute only a small
proportion of infiltrating leukocytes in EAE or MS lesions
(30). Secondarily recruited inflammatory cells account for
the vast majority of infiltrating cells and play a pivotal role
in CNS tissue damage (31). Although the detailed mecha-
nisms by which inflammatory cells influx into the CNS
compartment are not completely understood, increasing
evidence suggests that chemokines, in concert with adhe-
sion molecules, are essential for this process (32). In EAE,
elevated expression of MCP-1 by CNS parenchymal cells,
tightly linked to clinical disease, has been demonstrated re-
peatedly (33–35). Further, anti–MCP-1 Abs blocked re-
lapses of adoptive transfer EAE in SJL mice (36). Addition-
ally, mice that lacked CC chemokine receptor 2 (CCR2),
the major receptor on monocytes for MCP-1, failed to de-
velop EAE after active immunization and were resistant to
induction of EAE by the adoptive transfer of primed T cells
from syngeneic wild-type mice (37, 38). It was uncertain
whether MCP-1 was the relevant ligand for CCR2 in
these experiments, as this receptor also responds to MCP-2,
MCP-3, and MCP-5. However, there is also support for
the possibility that regulation of Th2 responses by MCP-1
could be important for the pathogenesis of EAE; in partic-
ular, MCP-1 was critical for the development of tolerance
after oral administration of a proteolipid protein (PLP) pep-
tide containing residues 139–151 (39)
Therefore, the phenotype of EAE in MCP-1–deficient
mice could not readily be predicted. On one hand, defec-
tive MCP-1–dependent monocyte recruitment might lead
to attenuated disease. Alternatively, if functional replace-
ment of MCP-1 by another MCP mediated monocyte ac-
cumulation in the CNS of these mice, defective Th2 re-
sponses might lead to very severe, nonremitting disease.
Finally, in view of redundancy in the immune/inflamma-
tory system, it remained possible that MCP-1–null mice
would manifest EAE identically to wild-type animals.
Given these considerations, the role of MCP-1 in the
pathogenesis of EAE merited further characterization.
These concerns are also likely pertinent for the human
disorder MS. Patients with active disease, manifest by clini-
cal attacks, showed significantly decreased MCP-1 in the
cerebrospinal fluid, as compared with controls. Of eight
chemokines measured, only MCP-1 was reduced in the
cerebrospinal fluid of patients with active MS. However,
abundant MCP-1 has been readily detected by immunohis-
tochemistry in autopsy brain sections containing MS lesions
(40–42). Therefore, the role of MCP-1 in the pathogenesis
of MS remains to be clarified.
In this report, we describe the phenotype of EAE in
MCP-1–null mice. These mice exhibited markedly re-
duced clinical and histological EAE after active immuniza-
tion and did not develop clinical disease after receiving en-
cephalitogenic T cells from wild-type animals. Expressions
of MCP-2, MCP-3, and MCP-5 in the CNS of both wild-
type and MCP-1–null mice with EAE were virtually iden-
tical. These findings indicated that MCP-1 was the major
ligand for CCR2 in murine EAE. In this EAE model, we
found that disruption of the MCP-1 gene led to an attenu-
ated Th1 autoimmune response and complimentarily in-
creased Th2 response. These results indicated a crucial role
for MCP-1 in generating CNS inflammatory reactions that
mediate the effector phase of myelin-specific Th1 autoim-
mune responses. Therefore, the data suggested that primed
encephalitogenic Th1 cells cannot manifest effector func-
tions in the CNS without recruiting hematogenous mac-
rophages. 
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Materials and Methods
 
Mice.
 
The disruption of the MCP-1 gene has been described
previously (2). MCP-1
 
2
 
/
 
2 
 
mice were backcrossed onto the
C57BL/6 (B6) strain for eight generations. One F8 MCP-1
 
2
 
/
 
2
 
mouse was further backcrossed to a B6 mouse (obtained from
The Jackson Laboratory). The heterozygous offspring were inter-
crossed to produce F9 wild-type (
 
1
 
/
 
1
 
), heterozygous (
 
2
 
/
 
1
 
),
and MCP-1
 
2
 
/
 
2 
 
mice. F10 mice were generated in a similar man-
ner. MCP-1
 
1
 
/
 
1
 
, MCP-1
 
2
 
/
 
1
 
, and MCP-1
 
2
 
/
 
2 
 
F9 and F10 mice
on the B6 background were used in this study.
MCP-1–deficient mice on the B6/129 background were also
backcrossed onto SJL for seven generations. MCP-1
 
1
 
/
 
1
 
 
 
and
MCP-1
 
2
 
/
 
2
 
 F7 mice on SJL background were used in this study.
Mice were genotyped using a PCR-based analysis of genomic
DNA extracted from tail clips. Primers MCP-1F, 5
 
9
 
-GGA GCA
TCC ACG TGT TGG C-3
 
9
 
 and MCP-1R, 5
 
9
 
-ACA GCT TCT
TTG GGA CAC C-3
 
9
 
 amplified a DNA fragment within the
MCP-1 gene. Primers NeoF, 5
 
9
 
-CGC TTC CTT TTT GTC
AAG AC-3
 
9
 
 and NeoR, 5
 
9
 
-ATC CTC GCC GTC GGG CAT
GC-3
 
9
 
 amplified a fragment in the neomycin resistance gene in-
sert. PCR reactions were performed in a PerkinElmer 9700 cy-
cler (annealing temperature, 50
 
8
 
C) and products were visualized
by electrophoresis on ethidium bromide–stained NuSeive GTG
 
®
 
agarose gel.
 
Rat Myelin Oligodendroglial Glycoprotein and Mouse Proteolipid
Protein Peptides.
 
Rat myelin oligodendroglial glycoprotein
(MOG)35–55 and mouse PLP139–151 peptides were obtained
from (BIO
 
?
 
SYNTHESIS) and purified by HPLC with a purity of
98%. The sequence of MOG35–55 was MEVGWYRSPFS-
RVVHLYRNGK and that of PLP139–151 was HSLGKWL-
GHPDKF.
 
Active Induction of EAE with MOG and PLP Peptides and Clinical
Evaluation.
 
Mice of 8–9 wk of age were subcutaneously in-
jected with 300 
 
m
 
g MOG35–55 emulsified in CFA (Difco) con-
taining 400 
 
m
 
g 
 
Mycobacterium tuberculosis
 
. Mice were intrave-
nously injected with pertussis toxin (Sigma-Aldrich) as indicated
in the figure legends on day 0 and 2 postimmunization (pi). The
immunization in SJL mice was carried out as described previously
(43). All mice were weighed, examined, and graded daily for
neurological signs in a double blind manner by one of us (J.
Wang) as follows: 0, no disease; 1, decreased tail tone or slightly
clumsy gait; 2, tail atony and moderately clumsy gait and/or poor
righting ability; 3, limb weakness; 4, limb paralysis; and 5, mori-
bund state. Disease relapse was determined when an increase of
one EAE score unit was observed. Signs of neurological impair-
ment were typically accompanied by an abrupt, substantial
weight loss (
 
.
 
7%). The average day of EAE onset was calculated
by adding the first day of clinical signs for individual mice and di-
vided by the number of mice in the group. Day of EAE onset in
mice that showed no clinical EAE was deliberately regarded as 1 d
after the experiment was terminated (44). The EAE index was
calculated by adding all the daily EAE scores to obtain cumulative
score and dividing by day of EAE onset. Active immunization
with MOG35–55 induced monphasic EAE in B6 mice and was
followed for 65 d. Chronic relapsing EAE induced by PLP139–
151 was monitored for 90 d.
 
T Cell Proliferation Assay.
 
Mice were killed and draining
lymph nodes (popliteal and inguinal lymph nodes [PILNs]) were
dissected on day 10 pi. Single cell suspensions (5 
 
3 
 
10
 
6
 
/ml) were
prepared and cultured in triplicate in 96-well flat-bottomed plates
(Falcon; Becton Dickinson) in 200 
 
m
 
l/well in the presence or ab-
sence of MOG35–55, PLP139–151, LPS, or anti-CD3 (R&D
Systems) in RPMI 1640 (GIBCO BRL) supplemented with 2
 
mM 
 
l
 
-glutamine, 100 U/ml penicillin, 100 
 
m
 
g/ ml streptomy-
cin, 10% FCS, and 5.5 
 
3 
 
10
 
2
 
5
 
 M 2-mercaptoethanol. Cells were
pulsed with [
 
3
 
H]thymidine (Amersham Pharmacia Biotech), 0.5
 
m
 
Ci/well 72 h after culture initiation, and incubated 10 h further.
Plates were harvested using a harvester (INOTECH). Incorpo-
rated radioactivity was measured in a MicroBeta PLUS liquid
scintillation counter with software v3.3 (Wallac Co.).
 
Cell Cultures and Cytokine Assay.
 
Mononuclear cell (MNC)
suspensions (5 
 
3 
 
10
 
6
 
/ml) were prepared from PILNs of mice that
had been immunized with MOG35–55 plus CFA for 10 d. Cells
were cultured at 2 
 
3 
 
10
 
6
 
/ml in RPMI 1640 supplemented as
above in cell culture tubes (Falcon; Becton Dickinson) in the
presence or absence of MOG35–55 and anti-CD3
 
e
 
 Ab at 5%
CO
 
2
 
 and 95% humidity. The supernatants were collected after
24, 48, and 72 h of in vitro restimulation and kept at 
 
2
 
80
 
8
 
C until
assay. Levels of IFN-
 
g
 
, IL-4, and IL-10 in sera and cell culture
supernatants were determined using ELISA kits commercially ob-
tained from R&D Systems. The standard curves were made on
the same occasion and the sensitivities for the methods were 2.0,
2.0, and 4.0 pg/ml for IFN-
 
g
 
, IL-4, and IL-10, respectively. All
samples were measured in duplicate and diluted if necessary.
 
Analysis of Chemokine and Chemokine Receptor mRNA Levels by
RNase Protection Assay.
 
Mice were anesthetized with sodium
pentobarbital and intracardially perfused through the left ventricle
with ice-cold PBS. Spinal cords were extruded by flushing the
vertebral canal with PBS, rinsed in PBS, and kept at 
 
2
 
80
 
8
 
C. To-
tal cellular RNA was prepared from spinal cord tissue by TRIzol
(Life Technologies). Quantification of CC chemokines and
chemokine receptors in CNS tissue was done by RNase protec-
tion assay (RPA) with Template Sets and In vitro Transcription
Kit (BD PharMingen) according to the manufacturer’s instruc-
tions. Protected fragments were visualized and quantified by au-
toradiography with PhosphorImager (Molecular Dynamics).
 
Reverse Transcription PCR Detection for Levels of MCPs, Cyto-
kine, CD3
 
e
 
, CD8, and Mb-1 mRNA.
 
Total RNA was extracted
from the PBS-perfused, snap-frozen spinal cords using TRIzol.
cDNA was synthesized using a RNA PCR Core kit (Gene-
Amp
 
®
 
; PerkinElmer). Glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) expression was used as an unregulated control and
amplified using primers: GAPDHf, 5
 
9
 
-GGT GGA GGT CGG
AGT CAA CG-3
 
9
 
 and GAPDHr, 5
 
9
 
-CAA AGT TGT CAT
GGA TGA CC-3
 
9
 
. MCP-2, MCP-3, and MCP-5 cDNA were
amplified by specific primer pairs, mcp-2f, 5
 
9
 
-ACA TCA CCT
GCT TGG TCT GGA AAA C-3
 
9
 
 and mcp-2r, 5
 
9
 
-ACT AAA
GCT GAA GAT CCC CCT TCG-3
 
9
 
; mcp-3f, 5
 
9
 
-CAC ATT
CCT ACA GAC AGC TC-3
 
9
 
 and mcp-3r, 5
 
9
 
-AGC TAC AGA
AGG ATC ACC AG-3
 
9
 
; and mcp-5f, 5
 
9
 
-CTC CTT ATC CAG
TAT GGT CC-3
 
9
 
 and mcp-5r, 5
 
9
 
-TCT CCC TCC ACC ATG
CAG AG-3
 
9
 
. IFN-
 
g
 
, IL-4, and IL-10 were amplified with
primer pairs: IFNgf, 5
 
9
 
-AGC GGC TGA CTG AAC TCA GAT
TGT-3
 
9
 
 and IFNgr, 5
 
9
 
-GTC ACA GTT TTC AGC TGT ATA
GGG-3
 
9
 
; il4f, 5
 
9
 
-TCG GCA TTT TGA ACG AGG TC-3
 
9
 
 and
il4r, 5
 
9
 
-GAA AAG CCC GAA AGA GTC TC-3
 
9
 
; and il10f, 5
 
9
 
-
CAT CAT GTA TGC TTC TAT GC-3
 
9
 
 and il10r, 5
 
9
 
-TAC
CTG GTA GAA GTG ATG CC-3
 
9
 
. CD3
 
e
 
 was detected with
primer pair: CD3ef, 59-ATG GAG CAG AGG AAG GGT
CTG-39 and CD3er, 59-TCA CTT CTT CCT CAG TTG
GTT-39. Levels of CD8 cDNA were detected using primer pair:
CD8f, 59-TCT GTC GTG CCA GTC CTT C-39 and CD8r,
59-CCT TCC TGT CTG ACT AGC GG-39, while that of Mb-1
(the gene encoding IgGa, expressed by B cells; reference 45):
Mb-1f, 59-GCC AGG GGG TCT AGA AGC-39 and Mb-1r,716 EAE in MCP-1–deficient Mice
59-TCA CTT GGC ACC CAG TAC AA-39. RNA Amplifica-
tion Kit SYBR Green I was used in all PCR reactions that were
performed in a real-time LightCycler system (Roche Molecular
Biochemicals). The level of specific mRNA was quantified and
expressed as the cycle number at which the LightCycler System
detected the upstroke of the exponential phase of PCR product
accumulation, and normalized by the level of GAPDH expression
in each individual sample. Therefore, levels of input mRNAs cor-
relate negatively with numbers of cycles.
Determination of Serum Anti–MOG35–55 IgG, IgG1, and
IgG2a. Detection of anti–MOG35–55 Abs was performed as
described previously (46). In brief, rat MOG35–55 peptide (0.1
ml/well, 3.0 mg/ml) was added to 96-well microtiter plate
(Nunc) in coating buffer and incubated at 148C overnight. After
being washed three times with PBS-Tween (0.1%), the plates
were blocked with 5% FCS in PBS for 2 h at room temperature.
Diluted sera (0.1 ml/well, 1:5 for IgG2a, 1:50 for total IgG and
IgG1) were added to and incubated at room temperature for 2 h,
followed by washing with PBS-Tween three times. A series of
serum dilutions were examined in the preliminary experiments.
The OD values obtained negatively correlated with the dilutions
of the samples. For the detection of IgG2a, alkaline phosphatase–
conjugated anti–mouse IgG2a (1:2,000 dilution; BD PharMingen)
was added and incubated for 2 h at room temperature, followed
by five washes. Color was developed by adding p-nitrophenyl
phosphate substrate (Sigma-Aldrich) and measurements were
performed at 450 nm in an ELISA reader (Wallac Co.). For the
detection of total IgG and IgG1, biotinylated anti–mouse IgG
(1:3,000; Sigma-Aldrich) and IgG1 (1:500; BD PharMingen) Abs
were added and incubated at room temperature for 2 h. After in-
cubation with ABC Vectastain (Vector Laboratories), the reaction
was developed with 2,29-azino-bis(3-ethylbenz-thiazoline-6-sul-
fonic acid) (ABTS) peroxidase substrate (Vector Laboratories) and
read at 405 nm in the ELISA reader. In each assay for IgG, IgG1,
or IgG2a, all the samples were measured in duplicate on a single
plate.
Flow Cytometry. Cells from the CNS were isolated as de-
scribed previously (37). Samples were washed in FACS® buffer
(1% FCS and 0.1% sodium azide in PBS). After blocking with
CD16/CD32 Fc Block (BD PharMingen), cells were stained for
surface markers with directly conjugated Abs in FACS® buffer.
Abs used were CD4-FITC, CD11b-PE, CD45–Cy-Chrome,
and CD8–Cy-Chrome, and were titrated using mouse peripheral
blood. All Abs were obtained from BD PharMingen.
Adoptive Transfer of EAE. Mice were immunized with 200
mg MOG35–55 peptide in CFA. Lymph nodes were harvested
and single MNC suspensions were prepared 10 d pi and cultured
in the presence of 30 mg/ml MOG35–55 and 20 ng/ml murine
rIL-12 (R&D Systems). After 4 d incubation, cells were collected
and washed in PBS. 2 3 107 living cells were intravenously in-
jected into wild-type or MCP-1–deficient mice. Recipients were
given 200 ng pertussis toxin intravenously on the day of cell
transfer and 48 h after transfer (37, 47). Mice were weighed and
EAE scored daily by an investigator (J. Wang) who was blinded
to mouse genotype or source of transferred cells. Mice were
monitored for 40 d after transfer.
Statistical Analyses. The Instat 2.02 software was used for the
analyses of the difference between the MCP-11/1, MCP-12/1,
and MCP-12/– mice. The Mann-Whitney U-test was used for the
comparisons of disease severity and cytokine and chemokine gene
expressions. A chi-square test was used for the comparisons of dis-
ease incidence in groups of MCP-11/1, MCP-12/1, and MCP-
12/2 mice. A P value ,0.05 was considered as significant.
Results
C57BL/6 MCP-1–deficient Mice Are Relatively Resistant
to Active EAE Induction with MOG35–55. MCP-11/1,
MCP-12/1, and MCP-12/2 F9 mice (n 5 9 in each group)
were immunized with 300 mg MOG35–55 plus 500 ng
pertussis toxin intravenous injection on day 0 and 2 pi.
One MCP-12/2 mouse died of immunization on day 4 pi.
The remainder of the mice, regardless of genotype, devel-
oped clinical EAE. MCP-11/1 mice showed EAE signs
around day 10 pi, consistent with previously reported re-
sults in C57BL/6 mice (44, 48). MCP-12/2 manifested sig-
nificantly delayed EAE with an average onset on day 21 pi
(Fig. 1). Three out of nine wild-type mice died of EAE,
and another three had to be killed because of moribund
state. None of the MCP-12/2 mice died of EAE or had to
be killed throughout the experiment and they recovered
from the disease significantly faster and more completely
than wild-type littermate controls. Heterozygote MCP-12/1
mice developed EAE with an intermediate kinetics and
severity. None of the MCP-12/1  mice died of EAE,
whereas three were killed in a moribund state due to severe
EAE. Analyses of CNS tissue histology revealed massive in-
flammatory infiltrates in wild-type control mice (111 to
1111 in regions of lumbar and sacral spinal cord, n 5 4;
Fig. 2 A) but markedly reduced inflammatory reaction in
MCP-1–null mice (1 to 11 in regions of corresponding
levels of affected spinal cord, n 5 4; Fig. 2 B; reference 49).
Examination of demyelination using Luxol Fast Blue stain-
Figure 1. Effect of MCP-1 gene disruption on MOG35-55–induced
EAE. F9 MCP-11/1, MCP-12/1, and MCP-12/2 mice were immunized
with MOG35–55 emulsified in CFA and intravenously injected with per-
tussis toxin (PT) on the day of immunization and 48 h later (500 ng/in-
jection). Three wild-type mice died of EAE and another three had to be
killed due to severe EAE attack. None of the MCP-12/1 mice died of
EAE, but three were killed. None of the MCP-12/2 mice died of EAE or
had to be killed. Shown are EAE score (mean 6 SD) in each group of
mice that had been followed throughout the experiment (n 5 3, 6, and 8
for MCP-11/1, MCP-12/1, and MCP-12/2 group, respectively). This
graph is representative of three experiments with similar results.717 Huang et al.
ing revealed significant reduction in MCP-12/2 mice com-
pared with their littermates controls 65 d after immuniza-
tion (data not shown).
F10 MCP-1–deficient mice and wild-type littermate
controls were analyzed in a subsequent experiment. As
pertussis toxin has been shown to increase the permeability
of the blood-brain barrier (BBB [50, 51]), enhance delayed
type hypersensitivity (DTH) responses and the production
of IFN-g (52–54), augment expression of CD80, CD86
on antigen-presenting cells and CD28 on T cells (55), and
T cell immune responses (55, 56), we reduced the amount
of pertussis toxin in the immunization to 200 ng per injec-
tion in an attempt to reduce the high death rate observed
in wild-type mice in the F9 experiments. In this experi-
ment, all MCP-11/1 and MCP-12/2 mice showed signs of
clinical EAE; none died of EAE or required killing. In
contrast to the MCP-11/1 mice that developed full-blown
EAE, the disease was largely suppressed with significantly
delayed onset and milder neurological impairment (Fig. 3)
and significantly less weight loss (data not shown) in
MCP-1–deficient mice. These data demonstrated that
MCP-1–null mice and CCR2-deficient mice exhibited
strikingly similar EAE phenotypes (37, 38) and suggested
that MCP-1 may be the relevant ligand for CCR2 in this
model.
Disruption of MCP-1 Gene Attenuates the Severity of PLP-
induced EAE and Reduces the Number of Relapses in SJL
Mice. 11 MCP-11/1  and 10 MCP-12/2  mice on SJL
background were immunized with PLP139–151 peptide
emulsified in CFA. One MCP-11/1 and two MCP-12/2
mice died of immunization within the first week after im-
munization. The reminder of MCP-11/1 mice (10/10) and
7 out of 8 MCP-12/2 mice showed clinical EAE. Com-
pared with the MCP-12/2 group, a significantly higher
percentage of MCP-11/1 mice died of EAE during the first
attack and relapses thereafter. Among the mice that sur-
vived the first attack, six MCP-11/1 mice had eight relapses
(four mice had one attack each and two had two attacks
each), whereas three out of seven MCP-12/2 mice had sin-
gle attacks. At day 90 pi, the average EAE index was signif-
icantly higher in MCP-11/1 group (n 5 4) than that in
MCP-12/2 group (n 5 7) (Fig. 4). These results implicated
a role for MCP-1 in eliciting relapses of EAE in this model.
These findings were consistent with previous reports show-
ing reduction of relapses using anti–MCP-1 Abs in a pas-
sive EAE model (36) and in mice receiving vaccine con-
taining naked DNA encoding for MCP-1 (57).
Figure 2. Spinal cord histology of MCP-11/1 and MCP-12/2 mice
with EAE score 4.0. Hematoxylin and eosin staining of longitudinal cryo-
sections. Note the numerous perivascular cuffs and subpial infiltrates (ar-
rows) as well as leukocytes disseminated in the white matter of MCP-11/1
mice (A), whereas merely fewer inflammatory infiltrates were found in
MCP-1–deficient mice (B).
Figure 3. Attenuated MOG35–55–induced EAE in MCP-1–null
mice. F10 MCP-12/2 mice (n 5 6) and their littermate wild-type con-
trols (n 5 6) were immunized with MOG35–55 in CFA and intrave-
nously injected with pertussis toxin (PT; 200 ng/injection). Shown are
EAE score (mean 6 SD) of individuals in each group.718 EAE in MCP-1–deficient Mice
There Is No Compensatory Upregulation of MCP-2, MCP-3,
or MCP-5 in the CNS of MCP-12/2 Mice with EAE. Be-
cause CCR2 is shared in common among all MCPs
(58–60), we analyzed MCP-2, MCP-3, and MCP-5
mRNA expression in the CNS of C57BL/6 mice with
MOG-induced EAE, using quantitative real-time reverse
transcription (RT)-PCR. Levels of MCP-2 and MCP-3
but not MCP-5 were elevated in CNS tissue from EAE
mice. There was no significant difference in MCP-2 ex-
pression in CNS tissue between MCP-11/1 and MCP-12/2
group (23.8 6 0.4 vs. 23.7 6 0.5, mean 6 SD; n 5 5 in
each group). No significant difference of MCP-3 expres-
sion in CNS tissue from MCP-11/1 (31.0 6 0.6, n 5 5)
and MCP-12/2 (33.1 6 2.6, n 5 5, P 5 0.4) mice was
found, whereas CNS MCP-5 expression in mice with EAE
was essentially undetectable (data not shown). The unal-
tered levels of MCP-2 and MCP-5 and a trend towards de-
creased expression of MCP-3 in MCP-12/2 mice (higher
PCR cycle number) uncovered no compensatory expres-
sion of other MCPs in this system, consistent with a pre-
vious report in autoimmune kidney disease model in
MCP-12/2 MRL-Faslpr mice (61). These findings sup-
ported the hypothesis that the similarity of EAE phenotype
in MCP-1– and CCR2-deficient mice is caused by absence
of the ligand, i.e., MCP-1 signaling pathway through its
major receptor CCR2.
T Cell Proliferation to MOG35–55 Peptide. To examine
the afferent limb of the immune response to MOG peptide
in wild-type and MCP-1–null mice, MNC suspensions
were prepared from PILNs primed with 200 mg MOG35–
55 peptide in CFA and rechallenged with MOG35–55 in
vitro.  MCP-1–deficient mice showed a nonsignificantly
higher recall T cell response than wild-type controls. No T
cell recall response was induced by stimulation with
PLP139–151 in vitro, a specificity control. No difference
in anti-CD3e–induced T cell proliferation was found be-
tween wild-type and MCP-1–deficient mice (data not
shown). These data indicated that the CD3 pathway was
intact in MCP-12/2 mice, and that MOG35–55–specific T
cells can be generated in MCP-1–deficient mice.
MCP-12/2 Mice Do Not Develop Clinical EAE in Passive
Transfer Model. An adoptive transfer EAE model was used
to further address whether MCP-1–null mice could de-
velop pathogenic autoimmune responses to MOG35–55
peptide. MCP-11/1 and MCP-12/2 B6 mice were immu-
nized with MOG35–55 peptide in CFA, and MNCs iso-
lated from draining lymph nodes were cultured in the pres-
ence of MOG35–55 peptide and IL-12 before transfer into
MCP-12/2  mice or littermate controls. As expected,
MCP-11/1 mice receiving MCP-11/1 T cells developed
clinical EAE (Fig. 5). MCP-12/2 T cells showed approxi-
mately the same encephalitogenic capacity in this adoptive
transfer model, resulting in a comparable incidence, sever-
ity, and clinical course of EAE in MCP-11/1 recipients. In
contrast, MCP-12/2 mice that received MCP-11/1 T cells
failed to develop clinical EAE (Fig. 5). This result indicated
that the attenuated EAE in MCP-12/2 mice was not
caused by impaired generation of encephalitogenic T cells.
The data also demonstrated that absence of MCP-1 expres-
sion in the recipient rendered the mice unable to respond
to encephalitogenic signals produced by wild-type T cells.
To dissect the mechanisms underlying the relatively re-
sistance to EAE induction in MCP-1–deficient mice, the
MOG35–55–induced EAE model was used in the follow-
ing mechanistic studies. To obtain samples from MCP-12/2
mice with full-blown EAE, F10 mice were immunized
with MOG35-55 in CFA plus 500 ng pertussis toxin per
injection.
Reduced CD11b1CD42/CD41 Ratio but Unchanged Lev-
els of CD3e and CD8 Transcripts in CNS Tissue from MCP-
12/2 Mice with EAE. Results described above suggested
that MCP-1–null mice were deficient in recruiting mono-
Figure 4. Milder disease and reduced number of relapses in PLP-
induced EAE MCP-12/2 SJL mice. MCP-12/2 SJL mice and their litter-
mate wild-type controls were immunized with PLP139–151 in CFA plus
intravenous injection of pertussis toxin as described in Materials and
Methods. Mice were monitored for 90 d after immunization. MCP-12/2
SJL mice showed significantly decreased EAE index, reduced number of
relapses, and nonsignificantly delayed disease onset.
Figure 5. Clinical course of EAE in MCP-12/2 and littermate control
recipient mice that received MOG35–55–reactive T cells generated from
MCP-11/1 or MCP-12/2 littermates. Data are presented as the EAE score
(mean 6 SD) in each group. Each group consists of four recipient mice.719 Huang et al.
cytes to the CNS during EAE. To address this issue, leuko-
cytes were isolated from CNS tissue of wild-type and
MCP-1–null mice with comparable severity of EAE, and
analyzed with flow cytometry. Cell numbers in prepara-
tions isolated from MCP-12/2 mice during EAE attacks
(score 4) were z1/3 of those from MCP-11/1 littermate
controls with comparable EAE severity. Compared with
MCP-11/1 littermate controls, MCP-12/2 mice showed a
sharply reduced percentage of CD11b1CD42 cells in the
CNS during EAE attacks (71.8 6 4.6% vs. 44.0 6 4.2%,
mean 6 SD, n 5 5 and 4, respectively; P , 0.0001). In
contrast, percentages of CD41 cells were relatively in-
creased in MCP-12/2 mice (20.2 6 5.9% vs. 39.8 6 2.7%,
mean 6 SD, n 5 6 and 4, respectively; P , 0.001; Fig. 6).
The CD41 infiltrating T cells expressed high levels of
CD11b (aMb2 integrin) both in MCP-11/1 (79.0 ± 5.6,
n 5 5) and MCP-12/2 (78.1 ± 6.8, n 5 5) mice, indicating
that most infiltrating CD41 T cells are activated.
To normalize percentage of CD41 T cells in the CNS
infiltrates of wild-type and MCP-1–null mice with EAE,
total CNS T cells were analyzed by determining levels of
CD3e in the CNS. We found no significant difference in
CNS CD3e mRNA levels between wild-type (0.789, n 5
5; CD3e/GAPDH) and MCP-12/2 (0.791, n 5 5; CD3e/
GAPDH) mice with clinical EAE scores of 3.5–4.0, sug-
gesting that total T cell numbers in the CNS of wild-type
and MCP-1–null mice with EAE were equivalent. There-
fore, the increased proportion of CD41 cells in the CNS
leukocyte infiltrates of MCP-1–null mice was caused by a
marked reduction in the number of CD11b1CD42 cells in
the CNS of MCP-1–deficient mice with EAE.
CD81 T cells play an important downregulatory role in
the pathogenesis of EAE (62). The possibility that the
milder clinical EAE phenotype observed in MCP-12/2
mice might be due to an increased number of CD81 T
cells in the CNS infiltrates was unlikely based on the fact
that levels of CD8-specific mRNA were virtually identi-
cal in MCP-12/2 (24.08 6 0.3, n 5 5) and MCP-11/1
(24.21 6 0.2, n 5 5) CNS tissue during EAE attack. The
passive transfer EAE model was used to examine further if
CD81 T cells can be preferentially recruited into CNS in
the absence of MCP-1. MOG35–55–reactive MCP-11/1
T cells were incubated in the presence of MOG35–55 and
IL-12, and were injected intravenously into MCP-11/1
and MCP-12/2 mice. To reduce the influence of second-
arily recruited macrophages in the CNS, recipient mice
were killed at day 3 and 4 after T cell transfer, before the
onset of clinical EAE. CNS-infiltrating T cells were recov-
ered and analyzed using flow cytometry. No difference was
found between MCP-11/1 and MCP-12/2 mice (data not
shown). These results demonstrated that disruption of
MCP-1 gene exerts no significant impact on the recruit-
ment of adoptively transferred T cells into inflammatory
CNS tissue. No significant difference in Mb-1 mRNA lev-
els was found in EAE-affected CNS tissue from MCP-11/1
and MCP-12/2 mice (data not shown).
We also examined the leukocyte infiltrates in MCP-12/2
mice at day 14 pi when the MCP-11/1 controls were un-
dergoing EAE attacks while the MCP-12/2 mice were still
free of EAE signs. Shown in Fig. 6 C are numerous
CD45highCD11b1 (mainly containing macrophages/acti-
vated microglia and activated T cells) isolated from MCP-
11/1 mice during EAE attack on day 14 pi. In contrast, the
majority of cells isolated from MCP-12/2  mice were
CD45lowCD11b1 microglia, and the components of the in-
filtrates (Fig. 6 D) were virtually the same as those from
healthy unimmunized mice (data not shown).
Diminished MOG35–55–specific Th1 Cytokine Responses
in MCP-1–null Mice. Significant changes in cytokine pro-
duction have been described in the Th1 immune response
that typifies MOG35–55 peptide-induced EAE in B6 mice
(35). Serum concentrations of IFN-g, IL-4, and IL-10
were determined by ELISA from mice immunized with
MOG35–55 on days 8 and 10 pi and at the peak of EAE
(day 14 pi in wild-type controls and 25 pi in MCP-1–defi-
cient mice). At day 8 pi, concentrations of IFN-g were
slightly but significantly higher in wild-type than in MCP-
1–deficient mice. This difference between wild-type and
MCP-1–deficient mice became strikingly evident on day
10 pi near the onset of EAE in wild-type controls. The on-
set of EAE was also associated with increased serum levels
Figure 6. Altered pattern of CNS cell infiltrates in MCP-1–null mice.
MCP-12/2 and MCP-11/1 littermate controls were immunized with
MOG35–55 and pertussis toxin (500 ng/injection) and killed at the peak
of EAE (score 4). Cells were isolated from the CNS and stained with
anti-CD4–FITC, anti-CD11b–PE, and anti-CD45–Cy mAbs. Compared
with wild-type controls (A), the percentages of CD11b1CD42 cells were
significantly decreased whereas the percentages of CD41 T cells increased
in MCP-12/2 mice (B). In contrast to MCP-11/1 mice that developed
full-blown EAE with numerous CNS CD11b1CD45high macrophages/
activated microglia and T cells (C), the majority of cells isolated from
CNS tissues of EAE symptom-free MCP-12/2 mice on day 14 pi were
CD11b1CD45low microglia (D).720 EAE in MCP-1–deficient Mice
of IFN-g in MCP-1–deficient mice, but the magnitude of
increase was significantly less than in MCP-11/1 mice (Fig.
7 A). Circulating IL-10 was detected at low levels in both
MCP-11/1 and MCP-12/2 mice before and after the onset
of EAE. Before EAE onset at day 8 pi (Fig. 7 B), serum IL-
10 was slightly but significantly higher in MCP-12/2 mice
than in wild-type controls. Serum IL-4 remained below
the limits of detection in both MCP-11/1 and MCP-12/2
mice at all time points.
These results were supported by data from in vitro
restimulation experiments, using draining lymph node
(PILN) cells from mice immunized with MOG35–55 in
CFA. Upon rechallenge with MOG35–55 peptide in vitro,
at all examined occasions during the cell culture, PILN
cells from MCP-12/2 mice secreted z50% less IFN-g than
cells from MCP-11/1 mice (Fig. 8, left). IL-4 and IL-10,
signature Th2 cytokines in EAE (26, 29, 63, 64), were also
measured. Although low levels of IL-10 were found in the
culture supernatants of restimulated PILN cells from both
MCP-11/1 and MCP-12/2 mice, significantly higher levels
of IL-10 were detected in cultures of cells from MCP-12/2
mice (Fig. 8, right). IL-4 was undetectable in all cell culture
supernatants.
CNS Cytokine mRNA Accumulation in MCP-12/2 and
Wild-type Mice with EAE. Local expression of IFN-g in
the CNS was analyzed by real-time RT-PCR. Signifi-
cantly higher geometric mean levels of IFN-g were found
in spinal cord tissue from MCP-11/1 mice at the peak of
EAE attacks (MCP-11/1: 27.7 6 0.3, mean 6 SD, n 5 4;
MCP-12/2: 29.9 6 0.8, n 5 4, P , 0.05). This result indi-
cated approximately a fourfold difference in the CNS ex-
pression of IFN-g between mice with intact and disrupted
MCP-1 genes, despite equal numbers of CNS-infiltrating
T cells (see above). There was no difference in IL-10 ex-
pression in CNS tissue between MCP-11/1 and MCP-12/2
mice with full-blown EAE. IL-4 gene expression was un-
detectable both in MCP-11/1 and MCP-12/2 mice (data
not shown).
Decreased Expression of IFN-g–inducible 10-kD Protein,
Macrophage Inflammatory Protein 1a, and RANTES in CNS
Tissue from MCP-12/2 Mice with EAE. CNS chemokine
expression was quantified using RPA, in tissues from MCP-
11/1 and MCP-12/2 mice equally affected by EAE (score
3.5–4.0). MCP-12/2 mice had significantly lower levels of
IFN-g–inducible 10-kD protein (IP-10), macrophage in-
flammatory protein (MIP)-1a, and regulated upon activa-
tion, normal T cell expressed and secreted (RANTES) tran-
scripts compared with wild-type littermate controls (Fig. 9).
Expression of MCP-3 was low in MCP-11/1 and MCP-
12/2 mice at the peak of EAE attack without significant dif-
ferences between MCP-1–deficient mice and littermate
controls, supporting the results obtained using real-time
RT-PCR. T cell activation gene (TCA)-3 expression in
the CNS of MCP-11/1 and MCP-12/2 mice with EAE
was near the lower limits of detection. No significant differ-
ence was found in CCR gene expression (data not shown).
However, there was a nonsignificant trend towards de-
creased levels of CCR2 expression in MCP-12/2 EAE
CNS tissue compared with wild-type controls. In the ab-
Figure 7. Quantitation of circulating cytokine levels in MCP-12/2 and
MCP-11/1 mice immunized with MOG35–55 in CFA and pertussis
toxin (500 ng/injection). Sera were collected at different times after im-
munization and measured for levels of IFN-g (A), IL-10 (B), and IL-4
(undetectable, data not shown). Data are mean 6 SD of five individual
mice in each group. This histogram is representative of two experiments
with similar results. WT, wild-type; KO, knockout.
Figure 8. Cytokine levels in cell culture supernatants of lymphocytes
from MOG35–55–immunized MCP-1–deficient mice and their litter-
mate controls. Cells from draining lymph nodes were restimulated with
MOG35–55 peptide in vitro. Supernatants were collected at different
times after immunization as indicated and measured for IFN-g, IL-10,
and IL-4 (undetectable, data not shown). Data represent means 6 SD and
are representative of two experiments with similar results. WT, wild-
type; KO, knockout.
Figure 9. Chemokine expres-
sion in spinal cords from MCP-
12/2 and MCP-11/1 mice im-
munized with MOG35–55 and
pertussis toxin (500 ng/injec-
tion). Spinal cords were col-
lected from mice that were
equally affected by EAE (score 4)
and levels of chemokine mRNA
were measured using RPA. Data
are presented as mean chemo-
kine products 6 SD. WT, wild-
type; KO, knockout.721 Huang et al.
sence of MCP-1, the presence of CCR2 in the affected tis-
sue might indicate the action of other CCR2 ligand(s). Al-
ternatively, the migration of CCR2-bearing cells into CNS
might be a bystander phenomenon.
Compelling evidence has shown that IP-10, MIP-1a,
and RANTES are potent factors that attract Th1 T cells
into sites of inflammation (65–70). Further, Th1/Th2 T
cells have been recently reported to differentially secrete
RANTES, lymphotactin, and TCA-3, respectively (71).
Enhanced expression of IP-10, MIP-1a, and RANTES in
MCP-11/1 EAE CNS tissue and undetectable TCA-3 ex-
pression in either MCP-11/1 or MCP-12/2 support the
notion that immune reactions within the CNS during EAE
attacks are Th1 biased and such responses are more pro-
nounced in mice with an intact MCP-1 gene.
Anti-MOG Ig Isotypes in MCP-12/2 and Wild-type
Mice. Sera from MCP-11/1 and MCP-12/2 mice with
EAE were analyzed for total IgG, IgG1, and IgG2a Abs
against the immunizing MOG35–55 peptide. Wild-type
and MCP-1–deficient mice produced similar amounts of
total MOG-specific IgG (Fig. 10). Despite the disparity in
clinical severity between wild-type and MCP-1–null mice,
this finding was not unexpected, given the results of exper-
iments using B cell–deficient mice, which showed that Ig
does not play an important pathogenic role in MOG35–55
peptide-induced EAE in B6 mice (48).
However, Ig isotype analyses differentiated the wild-type
and MCP-1–deficient mice. Levels of anti-MOG35–55
IgG1 Abs in wild-type controls remained low from day 14
pi through day 60 pi (Fig. 10) and were not elevated at in-
termediate time points (data not shown). In contrast, signif-
icantly higher levels of anti-MOG35–55 IgG1 Abs were
evident in MCP-12/2  mice (Fig. 10). Levels of anti-
MOG35–55 IgG2a Abs showed a trend towards elevated
levels in wild-type controls on day 14 pi, whereas no dif-
ference between wild-type and MCP-1–null mice was
found on day 60 pi (Fig. 10).
Taken together, these results suggest that a polarized
MOG35–55–induced Th1 immune response in wild-type
mice leads to a suppressed Th2 response, characterized by
undetectable IL-4, lower levels of IL-10, lower levels of
anti-MOG35–55 IgG1, and higher levels of IgG2a. In this
model, the absence of MCP-1 results in a shift towards a
Th2-biased response, with reduced production of IFN-g,
enhanced secretion of IL-10, and higher levels of IgG1.
Discussion
We and others have previously shown that MCP-1 was
markedly elevated in the CNS of SJL and B6 mice with
EAE (33, 35) and levels of MCP-1 expression correlated
with the severity of relapsing EAE (72). Anti–MCP-1 Abs
blocked relapses of EAE (36). CNS MCP-1 is largely pro-
duced by parenchymal astrocytes (34). MCP-1 expression
by astrocytes in MS brain lesions has also been convinc-
ingly documented (40–42).
However, these studies did not establish a primary role
for MCP-1 in disease pathogenesis. In recent definitive
studies of EAE using CCR2-deficient mice (37, 38), the
relevant ligand for the deleted receptor was not defined.
Moreover, MCP-1 exhibits attributes that argue for a role
in restraining autoimmune demyelination. In particular,
MCP-1 exerts a direct or indirect (via IL-4) impact on Th2
T cell development (11). Further, the presence of MCP-1
in in vitro cell culture systems decreased the encephalitoge-
nic potential of T cells directed to PLP139–151 (36). NK
cells that inhibited the encephalitogenic potential of auto-
aggressive T cells in DA rats produced high levels of MCP-1
in vitro (73). The role(s) of MCP-1 in the pathogenesis and
development of EAE (MS) has therefore been uncertain.
Using gene-targeted mice, we demonstrate that lack of
MCP-1 delays the onset of EAE and ameliorates its sever-
ity, by reducing the accumulation of inflammatory leuko-
cytes within CNS. This phenotype was associated with im-
paired MOG35–55–specific Th1 immune responses.
Impaired macrophage recruitment into the CNS, as in-
dicated by reduced total number of cells and percentage of
CD11b1CD4511CD42  cells recovered from CNS in
MCP-1–deficient mice in our study, is consistent with the
reduction of macrophages in MCP-12/2 mice in contact
hypersensitivity responses (2), in kidney and lung lesions of
MCP-12/2 MRL-Faslpr mice (74), in aortic walls of MCP-1
and low density lipoprotein receptor double-deficient mice
(75), and in atherosclerosis plaques from MCP-12/2 mice
that overexpress apolipoprotein B (76).
Compelling evidence suggests that macrophages and
their products can be detrimental in EAE and human MS.
Expression of MHC class II is markedly elevated in EAE
and MS (77), costimulatory molecules such as CD80,
CD86 expressed mainly by macrophages have been dem-
onstrated in MS lesions (78), and blockade of CD28/
CD80, CD86 pathway prevents epitope spreading and
Figure 10. Serum concentrations of
anti-MOG35–55 IgG, IgG1, and IgG2a
Abs in MCP-12/2 and MCP-11/1 lit-
termate controls after immunization
with MOG35–55 plus pertussis toxin
(500 ng/injection). Indicated are days pi
when sera were collected. Data are ex-
pressed as mean 6 SD, n 5 6, in each
group. *P  5 0.08, #P  , 0.01. WT,
wild-type; KO, knockout.722 EAE in MCP-1–deficient Mice
clinical relapses of EAE (79). B7-1/B7-22/2 mice are resis-
tant to EAE induction (47). Similarly, blocking of interac-
tions between CD40 on macrophages and CD40L on T
cells has been shown to effectively prevent EAE (80).
Products of macrophages like TNF-a, IFN-g, and nitric
oxide have also been demonstrated to be critical in the ef-
fector phase of EAE (81, 82). Macrophage depletion inhib-
its the induction of EAE (83). The absence of clinical EAE
in MCP-12/2 recipients of wild-type encephalitogenic T
cells further indicates the importance of CNS MCP-1 ex-
pression in recruiting macrophages to the CNS. We pro-
pose that it is the failure to recruit significant number of
macrophages into CNS that constitutes the principal mech-
anism for resistance to EAE induction in MCP-1–deficient
mice. Based on these studies, we cannot exclude the possi-
bility that MCP-1 may directly alter trafficking pattern of
dendritic cells in periphery or CNS, expression of costimu-
lators, inflammatory cytokines, and adhesion molecules.
Further studies are underway to address these issues.
As several studies have shown that MCP-1 is a critical
factor for T cell commitment to the Th2 phenotype, we
did not anticipate that MCP-1 gene disruption would re-
sult in reduced MOG35–55–specific Th1 immune re-
sponse in these EAE experiments. Our results show that
MOG35–55–specific MCP-12/2 T cells secreted a large
amount of IFN-g, although less than MCP-11/1 T cells,
but undetectable levels of IL-4. In view of the reciprocal
regulation between IFN-g and IL-10, the enhanced in
vitro secretion of IL-10 by MCP-12/2 T cells might be
secondary to reduced levels of IFN-g. However, increased
expression of IL-10 was not observed in vivo as demon-
strated by the equal amount of IL-10 transcripts in MCP-
11/1 and MCP-12/2  EAE CNS tissue. The fact that
MOG35–55–reactive MCP-12/2 T cells mediated severe
EAE in wild-type recipient mice in the passive transfer
EAE model further suggests that they were Th1 polarized.
An explanation for the equal encephalitogenic capacity of
MCP-12/2 T cells compared with MCP-11/1 T cells could
be that the defective IFN-g production by MCP-12/2 T
cells might be corrected by the presence of IL-12 in the cell
culture system (84). Alternatively, IFN-g concentrations
beyond a threshold may be dispensable for encephalitoge-
nic potential. T cells from MCP-1–null mice were shown
to produce lower levels of IFN-g in vitro upon MOG35–
55 restimulation in our studies, and MCP-12/2 splenocytes
secreted z50% less IFN-g when restimulated with Schisto-
soma mansoni eggs in vitro (2), implying a role for MCP-1
in maximal expression of this cytokine under some circum-
stances. On the premise that MCP-1 is the major ligand for
CCR2 in this model, our results are consistent with what
has been recently reported in CCR2-deficient mice (38).
Thus, a dual function is suggested for MCP-1 in regulating
T cell immune responses: promoting Th2 immune re-
sponses in certain circumstance while facilitating Th1 re-
sponses in others. Such difference is not uncommon when
molecules were tested in different animal strains, disease
models, and using different immunogens.
We propose that the role of MCP-1 in EAE became
manifest because of the extreme Th1 polarization impli-
cated in this model. The impaired ability to mount Th2 re-
sponses was not relevant in these experiments because the
disease was severely attenuated by the reduction of mac-
rophage recruitment to the CNS. Such reduction of mac-
rophage reaction might subsequently result in reduced Th1
immune responses. Remarkably, in the absence of re-
cruited macrophages, highly polarized Th1 cells became
unable to express the Th1 effector program, most clearly
demonstrated by decreased circulating and CNS IFN-g
and failure to elicit EAE in MCP-1–deficient mice by
MOG-primed MCP-11/1 encephalitogenic T cells.
Taken in the context of recent reports (37, 38), our re-
sults indicate that the MCP-1/CCR2 ligand/receptor pair
is critical for the expression of EAE in mice. In turn, these
findings motivate a continuing effort to characterize the
function of this multipotential chemokine in human dis-
ease.
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